0.66
-0.0107(-1.61%)
Currency In USD
Address
828 Winter Street
Waltham, MA 02451
United States of America
Phone
617 430 4680
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
October 22, 2021
| Name | Title | Pay | Year Born |
| Rene Russo | President, Chief Executive Officer & Director | 966,228 | 1975 |
| Katarina Luptakova | Chief Medical Officer | 661,890 | 1976 |
| Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer | 786,196 | 1982 |
| Scott Coleman | Chief Development Officer | 0 | N/A |
| Uli Bialucha | Chief Scientific Officer | 0 | N/A |
| Kevin Brennan | Senior Vice President of Finance & Accounting | 0 | 1970 |
| Nathan McBride | Chief Information Officer | 0 | N/A |
| Caroline Hensley | Chief Legal Officer | 0 | N/A |
| Ruth du Moulin | Senior Vice President of Medical Affairs | 0 | N/A |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.